Is capmatinib (Touradda) effective quickly and analysis of treatment response time

Capmatinib (Capmatinib) is an oral selective MET tyrosine kinase inhibitor, mainly used for treatment patients with pan>METexon14skipping mutations in non-small cell lung cancer (NSCLC). It blocks tumor cell proliferation and metastasis by inhibiting the MET signaling pathway, thereby delaying disease progression. As a targeted drug, capmatinib usually has no obvious effect on patients with unrelated mutations of RET or EGFR, so patients need to undergo genetic testing to confirm their MET mutation status.

Clinical studies show that capmatinib usually works faster in patients positive for METexon14 skipping mutations. Most patients can observe tumor shrinkage or stabilization of lesions on imaging within 4 to 8 weeks of taking the drug. Some patients have experienced symptom improvement during short-term follow-up, such as cough relief, respiratory function improvement, or pain relief. Compared with traditional chemotherapy, capmatinib has a significantly faster onset of action and can quickly improve patients' quality of life.

The efficacy and response time of capmatinib are affected by many factors, including tumor load size, mutation type, patient constitution and drug metabolism ability. When there is a high tumor burden or other genetic mutations, the response time may be prolonged; abnormal liver and kidney function or combined medication may also affect blood concentration, thereby delaying efficacy. Clinicians usually use imaging examinations and symptom assessment in the early stages of treatment to adjust the medication regimen in a timely manner to optimize the efficacy.

In clinical practice, capmatinib treatment needs to be combined with regular imaging review, hematology testing and adverse reaction monitoring. Common side effects include edema, nausea, fatigue, and increased liver function indicators. Patients should follow the doctor's instructions to take medication regularly, avoid missing doses, and report side effects in a timely manner. Overall, capmatinib is effective quickly, but the maintenance of efficacy and long-term safety still need to be ensured through regular follow-up and individualized adjustments.

Reference link:https://www.drugs.com